D
David A. Cooper
Researcher at Pfizer
Publications - 965
Citations - 81765
David A. Cooper is an academic researcher from Pfizer. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Viral load. The author has an hindex of 117, co-authored 903 publications receiving 69249 citations. Previous affiliations of David A. Cooper include Boston Children's Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Changes to AIDS dementia complex in the era of highly active antiretroviral therapy
TL;DR: A proportional increase in ADC compared with other ADIs and a marked increase in the median CD4 cell count at ADC diagnosis have occurred since the introduction of HAART in Australia, suggesting that HAART has a lesser impact on ADC than on otherADIs, with the poor CNS penetration of many antiretroviral agents a possible explanation.
Journal ArticleDOI
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
Martin Markowitz,Javier O Morales-Ramirez,Bach-Yen Nguyen,Colin Kovacs,Roy T. Steigbigel,David A. Cooper,Ralph Liporace,Robert S. Schwartz,Robin Isaacs,Lucinda R. Gilde,Larissa Wenning,Jing Zhao,Hedy Teppler +12 more
TL;DR: MK-0518 showed potent antiretroviral activity as short-term monotherapy and was generally well tolerated at all doses, and part 2 of the study, a dose-ranging 48-week trial of MK-05 18 versus efavirenz in a combination regimen, has been initiated.
Journal ArticleDOI
Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial
Augusto Azuara-Blanco,Jennifer Burr,Craig R Ramsay,David A. Cooper,Paul J. Foster,David S. Friedman,Graham Scotland,Mehdi Javanbakht,Claire Cochrane,John Norrie +9 more
TL;DR: Clear-lens extraction showed greater efficacy and was more cost-effective than laser peripheral iridotomy, and should be considered as an option for first-line treatment.
Journal ArticleDOI
Interleukin-2 therapy in patients with HIV infection.
Donald I. Abrams,Yves Levy,M. H. Losso,Abdel Babiker,Gary Collins,David A. Cooper,Janet Darbyshire,Sean Emery,Lawrence Fox,Fred M. Gordin,H C Lane,Jens D Lundgren,Ronald T. Mitsuyasu,James D. Neaton,Andrew N. Phillips,Jean-Pierre Routy,Giuseppe Tambussi,Deborah Wentworth +17 more
TL;DR: Despite a substantial and sustained increase in the CD4+ cell count, as compared with antiretroviral therapy alone, interleukin-2 plus antireteviral therapy yielded no clinical benefit in either study.
Journal ArticleDOI
Relation between HIV viral load and infectiousness: a model-based analysis
TL;DR: The analyses suggest that the risk of HIV transmission in heterosexual partnerships in the presence of effective treatment is low but non-zero and that the transmission risk in male homosexual partnerships is high over repeated exposures.